GLP-1s and the Brain: What Research on Addiction and Mood Shows

Researchers are studying whether GLP-1 medicines affect outcomes beyond their approved uses. The clinical results discussed below do not establish an approved addiction or mood treatment.

The study below evaluated a particular population and treatment setting; it does not establish a universal effect on cravings.

No. It means one well-run trial, in a specific group, saw a signal worth chasing. Treating addiction is a regulated medical claim, and no GLP-1 is FDA-approved for it. The medication was studied here as a research question, paired with therapy, in people who also had obesity. Generalizing past that is exactly what the researchers warned against. Under study, not approved ¹.

A 2026 randomized double-blind trial compared weekly semaglutide with placebo plus cognitive behavioral therapy in 108 adults with moderate-to-severe alcohol use disorder and obesity. At 26 weeks, semaglutide produced a greater reduction in heavy-drinking days. This early result does not establish an approved addiction treatment.

The mood question ran the opposite direction from old fears. For years, labels carried a warning about suicidal thoughts. In 2026, the FDA reviewed the data and asked for that warning to come off several GLP-1 products. A meta-analysis of 91 placebo-controlled trials covering more than 107,000 patients found no increased risk of psychiatric adverse events ²⁴.

The 2026 FDA review did not find increased suicidal behavior, suicidal thoughts, or related psychiatric adverse events in the analyses reviewed. This does not guarantee that an individual cannot experience mood symptoms; tell your clinician about new or worsening symptoms.

Are GLP-1s approved to treat addiction? No. As of mid-2026, no GLP-1 is FDA-approved for any addiction. The alcohol findings come from research, including one 26-week trial in people who also had obesity. Treating addiction is a regulated claim, and this use stays under study ¹.

Do GLP-1s cause depression or suicidal thoughts? The 2026 FDA review found no increased suicidal behavior or ideation in the reviewed evidence and requested warning removal. Tell your clinician about new or worsening mood symptoms. If you are in a mental-health crisis, call or text 988 in the United States; call 911 for immediate physical danger or a medical emergency.

Here is the practical skill. When a headline says a GLP-1 "fights addiction" or "lifts mood," check three things. Is there a dated, named study behind it? Does the study group match you? And does it say the use is approved or under research? Most viral posts skip all three ³.

GLP-1 brain research is one of the most interesting stories in medicine right now. In 2026, an alcohol trial showed real promise, and big safety reviews eased old mood fears. Both findings are early. Neither is FDA-approved for addiction or mood. Individual results vary, and headlines move faster than evidence ¹².

Read past the headline. Find the dated study, check the group it studied, and check whether the use is approved or under research.